Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
PTLA closed up 0.36 percent on Thursday, October 19, 2017, on 65 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Nov 6
|Weak or Absent||Up||Down||Down|
|See historical PTLA trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 19||Hammer Candlestick||Bullish||0.00%|
|Oct 19||Stochastic Buy Signal||Bullish||0.00%|
|Oct 19||Lower Bollinger Band Walk||Other||0.00%|
|Oct 18||Lower Bollinger Band Walk||Other||0.36%|
|Oct 17||Bollinger Band Squeeze||Range Contraction||-0.06%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more PTLA news...
|52 Week High||67.1|
|52 Week Low||15.68|
|200-Day Moving Average||44.4586|
|50-Day Moving Average||55.257|
|20-Day Moving Average||53.22|
|10-Day Moving Average||52.648|
|Average True Range||1.8855|
|Chandelier Exit (Long, 3 ATRs )||50.2135|
|Chandelier Exit (Short, 3 ATRs )||55.0165|
|Upper Bollinger Band||56.4298|
|Lower Bollinger Band||50.0102|
|Percent B (%b)||0.07|
|MACD Signal Line||-1.0223|
|Market Cap||2.91 Billion|
|Num Shares||57.6 Million|
|Price-to-Earnings (P/E) Ratio||-11.09|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||52.15|
|Resistance 3 (R3)||51.97||51.22||51.87|
|Resistance 2 (R2)||51.22||50.80||51.32||51.78|
|Resistance 1 (R1)||50.85||50.53||51.04||51.03||51.68|
|Support 1 (S1)||49.73||49.68||49.92||49.91||49.26|
|Support 2 (S2)||48.98||49.41||49.08||49.16|
|Support 3 (S3)||48.61||48.98||49.07|
|Support 4 (S4)||48.79|